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Abstract
Background: Microtubule drugs are effective anti-cancer agents, primarily due to their ability to induce mitotic arrest and
subsequent cell death. However, some cancer cells are intrinsically resistant or acquire a resistance. Lack of apoptosis
following mitotic arrest is thought to contribute to drug resistance that limits the efficacy of the microtubule-targeting anti-
cancer drugs. Genetic or pharmacological agents that selectively facilitate the apoptosis of mitotic arrested cells present
opportunities to strengthen the therapeutic efficacy.
Methodology and Principal Findings: We report a natural product Celastrol targets tubulin and facilitates mitotic cell death
caused by microtubule drugs. First, in a small molecule screening effort, we identify Celastrol as an inhibitor of neutrophil
chemotaxis. Subsequent time-lapse imaging analyses reveal that inhibition of microtubule-mediated cellular processes,
including cell migration and mitotic chromosome alignment, is the earliest events affected by Celastrol. Disorganization, not
depolymerization, of mitotic spindles appears responsible for mitotic defects. Celastrol directly affects the biochemical
properties of tubulin heterodimer in vitro and reduces its protein level in vivo. At the cellular level, Celastrol induces a
synergistic apoptosis when combined with conventional microtubule-targeting drugs and manifests an efficacy toward
Taxol-resistant cancer cells. Finally, by time-lapse imaging and tracking of microtubule drug-treated cells, we show that
Celastrol preferentially induces apoptosis of mitotic arrested cells in a caspase-dependent manner. This selective effect is
not due to inhibition of general cell survival pathways or mitotic kinases that have been shown to enhance microtubule
drug-induced cell death.
Conclusions and Significance: We provide evidence for new cellular pathways that, when perturbed, selectively induce the
apoptosis of mitotic arrested cancer cells, identifying a potential new strategy to enhance the therapeutic efficacy of
conventional microtubule-targeting anti-cancer drugs.
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Introduction
Microtubules (MTs), filamentous polymers of alpha- and beta-
tubulin heterodimer, are essential cytoskeleton structures that
control fundamental cellular processes, such as cell division,
migration, intracellular transport and signaling (for review[1]).
MTs are dynamic in nature and constantly undergo phases of
shrinkage and re-growth, a process known as ‘dynamic instability’.
This dynamic property underlies the vast majority of MT-based
cellular processes [1]. The overall dynamics of MTs vary in
different cell types and cellular contexts and are regulated at the
multiple levels, including post-translational modifications of
tubulin itself and interactions with a wide variety of MT binding
proteins [2,3,4,5,6].
Under physiological conditions, the most dramatic reorganiza-
tion of MTs occurs at the onset of mitosis when the interphase
MTs are depolymerized and repolymerized to form mitotic
spindles. The spatio-temporal assembly and dynamic behavior of
mitotic spindles are critically important for proper alignment and
segregation of the duplicated chromosomes, failure of which leads
to cell death or genomic instability (for review [7]). The mitotic
spindles are particularly sensitive to various natural and synthetic
MT drugs that impair their assembly and functions, leading to
mitotic arrest and subsequent cell death. Due to this activity, MT
drugs are most widely used to treat human cancers. However,
some cancer cells are intrinsically resistant and the drug-exposed
cancer cells often acquire a resistance.
Discovery and exploitation of structurally different new types of
antimicrotubule agents may overcome such problem. For
example, the clinical utility of structurally different MT stabilizers
to overcome the Taxol-resistance has been reported [8,9,10]. The
complementary approaches may include a combined inhibition
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proteins [11]. Nevertheless, given the essential functions of MTs in
various cellular processes, some degrees of cytotoxicity to normal
cells appear inevitable.
It has been reported that the relative resistance of various
human cancer cell lines to common antimitotic agents is correlated
with lack of cell death rather than mitotic arrest [12]. This finding
is consistent with both clinical observations and animal model
experiments that identified the degree of cell death following
Taxol treatment determined the overall outcome of its efficacy
[13,14]. Therefore, genetic or pharmacological agents that
selectively facilitate apoptosis of mitotic arrested cells (i.e.
proliferating cancer cells) present opportunities to strengthen the
efficacy of MT drugs, with little impact on the drug-exposed
interphase cells (i.e. non-dividing normal cells).
In the course of small molecule screening effort (unpublished
result), we identified a natural product Celastrol, traditionally
known for its anti-inflammatory and anti-cancer activities, as an
inhibitor of neutrophil chemotaxis. By employing a series of
experiments which include the time-lapse imaging of cell
migration and chromosome alignment as well as biochemical
and cell biological approaches, we revealed that inhibition of MT
functions was one of the earliest cellular events affected by the
novel tubulin-targeting activity of Celastrol. We further demon-
strated that this unique activity could be exploited to induce
apoptosis of Taxol-resistant cancer cells, and to selectively facilitate
the mitotic cell death of MT drug-arrested cancer cells. These
findings provide a molecular explanation for the anti-inflamma-
tory and anti-cancer activity of Celastrol, and present a potential
strategy to enhance the mitotic cell death induced by conventional
microtubule-targeting anti-cancer drugs.
Materials and Methods
Cell culture and generation of Taxol-resistant cell line
Both HEK293 and HeLa cell lines were obtained from
American Type Culture Collection (ATCC), and were maintained
in DMEM supplemented with 10% fetal bovine serum and 1%
penicilin and streptomycin under 5% CO2.
To generate a Taxol-resistant cell line, HeLa cells stably
expressing the EGFP fused to Histone 2B were generated. These
cells were then plated into 60 mm-culture dish (1610
6) in the
presence of 0.5 nM of Taxol. After 72 hours, the live cells were
collected and re-plated in the presence of the same concentration
of drug. This procedure was repeated at least three times for a
given drug concentration. The concentration of Taxol was
gradually increased to a final concentration of 5 nM. The resistant
cells designated as H2B-TxR were maintained and propagated in
the presence of 5 nM Taxol.
Reagents and antibodies
Celastrol was purchased from EMD Biosciences and all other
chemicals unless specified were from Sigma Aldrich and Tocris
Bioscience. Mouse monoclonal antibodies for gamma-Tubulin
(T3320), alpha-Tubulin (T6199), and beta-Tubulin (T4026) were
from Sigma Aldrich; Rabbit polyclonal antibodies for alpha
Tubulin (ab18251) and beta-Tubulin (ab6046) were from Abcam.
The HRP-conjugated anti-rabbit and anti-mouse secondary
antibodies were from Amersham Biosciences; all other antibodies
were purchased from Cell Signaling Technology.
Neutrophil purification and EZ-taxiscan chemotaxis assay
Human peripheral blood neutrophils were purified as previously
described [15]. The EZ-taxiscan chamber (Effector Cell Institute,
Tokyo, Japan) was assembled with a 260 mm wide 64 mm thick
silicon chip according to the manufacturer instruction. The
inhibitor-treated neutrophils (3610
6/ml) were mixed in RPMI
(0.1% BSA) and loaded to the lower chamber (3000 cells per well).
One microliter of fMLP (100 nM final) was added to the upper
chamber. The migrating neutrophils toward the upper chamber
were imaged every 30 seconds for 20 minutes. The movie was
analyzed using DIAS software (Solltech, Oakdale, IA) to calculate
the speed.
Western blot and immnunostaining. Preparation of total
cell lysates, Western blot, and other standard molecular biological
techniques were essentially the same as described previously [16].
For the analysis of mitotic nuclei, cells were fixed in the presence of
3% PFA (pre-warmed) for 5 minutes before DAPI staining. For
immunostaining of microtubules, cells were plated into a 35 mm-
glass bottom dish (MatTek Corp.) and fixed for 5 minutes in pre-
chilled (220uC) methanol. After washing three times in PBS-Triton
X-100 (0.05%), the fixed cells were permeabilized for 30 minutes in
5% normal goat serum containing 0.3% Triton X-100. The diluted
antibody (1:2000 for primary and 1:1000 for secondary antibody) in
the same solution was added and incubated for 3 hours at room
temperature. After washing three times in PBS-Triton X-100, the
Alexa fluor dye-conjugated secondary antibody was added and
incubated for 1 hour at room temperature. The staining was
visualized under the fluorescent microscope (Olympus IX71) and
the image was taken using the 100 X objective lens. To examine
the defects of the positioning of two centrosomes with respect to
substratum in Celastrol-treated mitotic cells, two images with
different focal planes, focused on the gamma-tubulin staining of
each pole, were taken along with alpha-tubulin staining in the
spindles (Figure S1B).
Biochemical assays for tubulins
The exponentially growing HEK293 cells were collected and
washed once in PBS. The cell pellet was frozen on dry ice for 15
minutes and lysed in the assay buffer containing 0.3% CHAPS,
200 mM GTP, and the protease inhibitor cocktail (Sigma Alderich)
in PBS. The lysate was kept on dry ice for 15 minutes and thawed
at room temperature. Once thawed, the cell lysate was
immediately centrifuged at 14,000 rpm for 5 minutes at 4 degree.
Only the freshly prepared cell lysate (2–4 mg/ml) was used in in
vitro oligomerization assay, typically in a 50 ml reaction volume.
After pre-incubation in the presence of drug for 10 minutes on ice,
the lysate was incubated at 37uC for 15 to 60 minutes. The
reaction was stopped by adding an equal volume of 2 X LDS
buffer and boiled for 5 minutes prior to SDS-PAGE. For the assay
with the purified tubulin (.99% from Cytoskeleton, Inc), the
tubulin solution was diluted to a concentration of 10 mg/ml in the
assay buffer, and the reaction was performed essentially the same
as the cell lysate. For immunoprecipitation, HEK293 cells were
lysed in the same buffer as above (typically 1 ml per 60 mm-
culture dish). The lysate was cleared by centrifugation and
incubated on ice for 10 minutes in the presence of different drugs.
The polyclonal alpha tubulin antibody (ab18251, Abcam) was
added (5 mg of antibody per 1 mg of protein per sample) and
incubated for 1 hour in the cold room before adding the protein
G/A-agarose slurry (30 ml per sample). After incubation for
additional 2 hour, the immunecomplex was washed three times in
the ice-cold assay buffer at 4uC before SDS-PAGE.
Caspase activity, cell viability, and proteasome activity
assay
The colorimetric caspase activity assay was carried out using the
crude cell extract in the presence of caspase substrate, Ac-DEVD-
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and washed once in PBS. Cells were lysed on ice for 10 minutes in
a buffer containing 0.1% CHAPS, 50 mM HEPES (pH 8.0),
12.5 mM NaCl, 0.1 mM EDTA, and 5 mM DTT freshly added.
The lysate was centrifuged for 5 minutes at 14, 000 rpm at 4
degree. The cleared lysate (approximately 200–400 mg of protein)
was mixed with the Ac-DEVD-pNA (200 mM final) in 100 ml
reaction volume in a 96-well assay plate. The plate was incubated
at 37uC and the enzyme activity was measured by reading the
absorbance at 405 nm for every 1 hour using the plate reader
(TriStar LB 941, Berthold Technologies). The cell viability was
determined by MTT assay as described previously [16]. To
measure proteasome activity, HEK293 cells (1610
6) were treated
with each chemicals (5 mM) for 1 hour, and lysed on ice for 15
minutes in 200 ml of lysis buffer (20 mM TrisHCl, pH 7.5;
150 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM beta-
Glycerophosphate; 1% Triton- X100). After clearing cell debris
by centrifugation at 4 degree, the extract was subjected to
proteasomal activity assay using the Proteasome-Glo
TM Chymo-
trypsin-Like Assay (Promega).
Time-lapse live cell imaging
For cell migration assay, HeLa cells expressing Histone H2B
EGFP (HeLa-H2B) were plated into a 35-mm culture dish
(4610
5) and cultured for 48 hours. The scratch was made using
the tip in the middle of dish and washed once in pre-warmed
Leibovitz’s L15 medium supplemented with 0.5% FBS. After 10
minutes of healing in the same medium, the drug was added and
the time-lapse movie was taken every 15 minutes for 150
minutes using the IPLab software. The migration area was
determined by subtracting the area occupied by cells at time 150
minutes with that of at time 0 minute for each drug. The relative
migration area was calculated by normalizing against the
control (DMSO-treated) group. For mitotic chromosome
alignment, HeLa-H2B cells were plated into a 35 mm-glass
bottom dish at 20% confluence and cultured for 48 hours. The
medium was replaced with Leibovitz’s L15 medium supple-
mented with 0.5% FBS. Immediately following the addition of
each drug, the prophase cells were identified under the
fluorescent microscope and the time-lapse movie was taken
every 5 minutes for 90 minutes. For apoptotic death of mitotic
arrested cells, HeLa-H2B cells growing exponentially (or around
70% confluence) in 35 mm-dish were replaced with 2 ml of
Leibovitz’s L15 (0.5% FBS) medium containing 10 nM
Vinblastine and cultured for 4 hours. After addition of each
drug, the time-lapse movie was taken every 15 minutes for
4 hours. The apoptotic death of only the ‘pre-arrested’ mitotic
cells, as identified by round morphology at time 0, was scored
and designated as ‘mitotic death’ (see Figure S4). The non-
mitotic cell death was defined as the adherent and flat cells
(drug-exposed interphase cells) died in the next two frames
(within 30 minutes). The apoptotic death of ‘newly-arrested’
mitotic cells during time-lapse imaging was not counted. To
determine the effects of Celastol on mitotic cells, we synchro-
nized and enriched mitotic HeLa-H2B cells by ‘double-
thymidine block’ [17]. Briefly, cells were grown to 20–30%
confluency and cultured for 19 hrs in the presence of thymidine
(2 mM), and incubated for 10 hours without thymidine. The
second block was carried out by culturing for 17 hours with
thymidine (2 mM). Cells were washed and incubated for
5 hours without thymidine, and the medium was replaced with
Leibovitz’s L15 (0.5% FBS) medium. Cells were cultured for
additional 4 hours before adding Celastrol, and the fate of
mitotic cells were tracked by time-lapse movie.
Results
Celastrol inhibits cell migration
Celastrol is one of the active compounds derived from plant
extracts traditionally used to treat the inflammatory symptoms [18].
Recruitment of immune cells to the site of inflammation precedes a
cascade of cellular events leading to inflammatory responses, and
inhibition of this recruitment can attenuate the inflammatory
processes. During a small molecule screening, Celastrol was
identified as an inhibitor of the fMLP-induced neutrophil
chemotaxis (unpublished result). Celastrol has been shown to
inhibit the proteasomal activity and modulate the heat shock
protein (HSP) 90 pathway [19,20,21]. Therefore, we examined the
effects of known inhibitors of these pathways, 17AAG for HSP90
and MG132 for proteasome, under the same experimental setting.
Compared with the control cells, the Celastrol-treated neutrophils
showed an approximately 50% reduction in migrating speed
toward a gradient source of fMLP (Movie S1 and S2). However,
no detectable effect was observed in the presence of other
chemicals. In addition, Gedunin, which has been shown to inhibit
the HSP90 pathway similar to Celastrol [20], also showed no
inhibitory effect (Figure 1A and B). Moreover, when tested in the
whole cell lysate assay, Celastrol showed a very little inhibitory
activity toward proteasome (Figure 1B). Thus, the effect of
Celastrol on neutrophil chemotaxis is not caused by the inhibition
of the proteasomal activity.
Next, we explored if this finding could be extended to other cell
types. A recent study showed that Celastrol inhibited TNF alpha-
induced tumor cell invasion through inhibition of gene expression
controlled by NF-k B pathway [22]. However, due to a longer
duration of drug exposure in this study, whether or not Celastrol
directly affected the motility of epithelial cells could not be
determined. Accordingly, we examined the direct effect of
Celastrol on tumor cell migration using a wound healing assay.
The confluent Hela cells were scratched, and time-lapse images of
migration toward the wounded area were taken. Consistent with
its effects on neutrophil chemotaxis, Celastrol effectively inhibited
cell migration, on average 60% reduction over the time course of
150 minutes (Movie S3 and S4). To rule out the possibility that
this inhibitory effect was due to the general cell toxicity, we pre-
treated cells with Celastrol for 3 hrs. Upon removal of drug, the
migration capacity of cells was fully restored, indicating this
inhibitory effect was reversible and was not caused by general
toxicity (Figure 1C and D). Similar with what was observed in
neutrophils, inhibition of either proteasome or HSP90 pathway
had no inhibitory effect under this experimental condition
(Figure 1C and D). These results indicate the presence of
cellular target(s) of Celastrol, insensitive to inhibition of the
proteasome or HSP90 pathway.
Celastrol impairs mitotic progression by inhibiting
chromosome alignment
The dynamic and coordinated regulation of cytoskeleton
network, such as actin filaments and microtubules, is critical for
migrating cells. The inhibitory effects on cell migration in both
neutrophil chemotaxis and epithelial wound-healing suggest a
possibility that Celastrol may interfere with the cytoskeleton
network. During mitosis, MT dynamics plays crucial roles in
alignment and segregation of chromosomes. Therefore, we
examined for abnormalities in the proportion of mitotic phases
upon Celastrol treatment. While the DMSO-treated HeLa cells
showed a similar proportion of prometaphase, metaphase, and
anaphase/telophase chromosomes, over 70 percent of chromo-
somes in Celastrol-treated cells displayed the ‘prometaphase-like’
Facilitated Mitotic Cell Death
PLoS ONE | www.plosone.org 3 April 2010 | Volume 5 | Issue 4 | e10318Figure 1. Celastrol inhibits cell migration. (A–B) Celastrol inhibits fMLP-induced neutrophil chemotaxis. (A) Freshly isolated human peripheral
blood neutrophils were pre-treated with each chemical for 30 minutes, and then subjected to fMLP-mediated chemotaxis for 20 minutes using the
EZtaxiscan. The first and the last images of the videos were shown for each drug. fMLP (100 nM), Celastrol (2 mM), 17AAG (4 mM), MG132 (10 mM), and
Gedunin (20 mM) were used in the indicated combination. (B) Left panel is the quantification of the migrating speed upon each drug treatment. Right
panel is the whole cell lysate assay of the proteasomal activity treated with each drug for 1 hour. The concentration of all chemicals was 5 mM. (C–D)
Celastrol reduces epithelial cancer cell motility. (C) The confluent HeLa cells were scratched using a tip. After 10 minutes of recovery, each drug was
added and the time-lapse images were taken every 15 minute for 150 minutes. The representative still images of the first (time 0) and the last (time
150) time points were shown. For the sample of ‘‘Celastrol-wash’’, cells were pre-treated with Celastrol for 3 hour before scratching; and the time-
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performed a prometaphase-arrest and release experiment
(Figure 2B). We first arrested cells at the prometaphase by
Nocodazole treatment, and the arrested cells were collected by
tapping the plate. Upon removal of Nocodazole, the mitotic
spindles are re-assembled, which align chromosomes to the
metaphase plane for the subsequent mitotic progressions to occur.
This release experiment was carried out in the presence of
different chemicals to assess their effects on the mitotic spindle
functions. In control group, almost half of the arrested cells have
progressed to anaphase during 30 minute-release (incubation)
period. However, in the presence of Celastrol, the majority of cells
were arrested in the prometaphase, while inhibition of HSP90 had
no effect. The proteasome inhibition by MG132 slightly
accumulated cells at the metaphase (Figure 2B). To further
validate these observations, we performed a live imaging of mitotic
cells (Figure 2C and D). Immediately following the addition of
each chemical, the prophase cells, as identified by the condensed
chromatids, were imaged as they undergo chromosome alignment
and segregation (Movie S5 and S6). In control group, the
prophase cells progressed to anaphase within 60 minutes.
However, in the presence of Celastrol, they failed to progress
and stayed in a prometaphase-like state. Consistent with the results
from the prometaphase-arrest and release experiment, inhibition
of HSP90 had no obvious defects. It is noteworthy that a long-term
inhibition of HSP90 will affect mitotic progression by impairing
the centrosomal functions [23,24,25]. However, under this short
period of inhibition condition, no obvious defect was detected. As
expected, inhibition of proteasome delayed the progression to
anaphase, since its activity is required for chromosome separation
(Figure 2C and D).
Celastrol disorganizes mitotic spindles
To better understand the effects of Celastrol at the cellular level,
we examined if the structure of MT was affected in treated cells.
Surprisingly, at the concentration of Celastrol (2–4 mM) that
inhibited cell migration and chromosome alignment, we found a
relatively intact MT structure in interphase cells (Figure 3A and
B). However, a significant disorganization of mitotic spindle was
seen in mitotic cells (Figure 3 A and B). During the
prometaphase, the mitotic spindles and the associated motor
proteins help align chromosomes at the metaphase plane. At this
stage, apart from the centrosomal localization, gamma-tubulin is
also localized to the spindles to help their assembly [1]. In
epithelial cells, the mitotic spindle is assembled in parallel to
substratum [26]. Consistent with this report, in most of control
HeLa cells (95%, n=25), two centrosomes as visualized by
gamma-tubulin staining were observed in the same focal plane of
100 x objective lens (Figure 3A and Figure S1A). However, in
Celastrol-treated cells, the spindle localization of gamma-tubulin
was significantly abolished (93%, n=42/45) and the plane of two
poles with respect to substratum was severely distorted, leaving two
centrosomes hardly in the same focal plane (78%, n=35/45) or
positioning them adjacent to each other (22%, n=10/45)
(Figure 3B and Figure S1B). These defects appeared to be
different from those caused by Vinblastine, a MT depolymerizer,
or Taxol a MT stabilizer, which mainly affect polymerization/
depolymerization of MT (Figure 3C and D). This observation
suggests that Celastrol disorganizes the mitotic spindles using a
different mechanism.
Celastrol causes structural defects of tubulin in vitro and
reduces its level in vivo
The Celastrol-induced functional defects of MTs could be
caused by inhibition of many cellular factors. We tested a
possibility that tubulin itself could be a direct target. Apart from
its well-established polymerization in vitro, which requires a high
concentration (above 1–2 mg/ml) and GTP, the tubulin hetero-
dimer manifests a variety of other biochemical properties,
including the GTP-independent oligomerization, intra- and
inter-molecular disulfide bond, non-disulfide bond cross-linking,
and non-enzymatic cleavage [27,28,29,30,31]. We examined if
Celstrol could affect any of these biochemical properties. As
previously reported, incubation of purified tubulin led to
oligomerization (or high molecular weight complexes) detectable
on a non-reducing condition (Figure 4A). The majority but not all
of these oligomers disappeared in a reducing condition (Figure
S2A). The amounts of remaining tubulin oligomers were variable
in each experiment and may represent SDS-resistant and non-
disulfide cross-linked tubulins [31]. The addition of GTP, which
stabilizes the tubulin structure, but not ATP, increased the level of
oligomers in both HEK293 cell lysates and purified tubulins,
indicating this oligomerization may require some degree of
structural stability (Figure S2B). Using this assay with HEK293
cell lysate, we found that Celastrol inhibited formation of tubulin
oligomers, whereas 18 beta-glycyrrhetic acid (18-bGCA), a
triterpene structurally similar to Celastrol, showed a much weaker
inhibitory effect (Figure 4A). A similar inhibitory effect was also
observed when purified tubulin was used (Figure S3).
This inhibitory effect could be due to destabilization (i.e.
unfolding) of tubulins in the presence of Celastrol. If this is the
case, then Celastrol may disrupt the dimeric interaction between
alph- and beta-tubulin. To directly test this possibility, we first
prepared cell lysates from control HEK293 cells, and the alpha-
tubulin was immunoprecipitated with a polyclonal antibody in the
presence of different amounts of Celastrol. The level of beta- and
gamma- tubulin in the resulting immunecomplex was examined.
Intriguingly, the amount of beta-tubulin was decreased in a
Celastrol-dose dependent manner, while that of gamma-tubulin
remained largely unaffected (Figure 4B). When tested under the
same experimental condition, the other MT drugs showed no such
effect (Figure 4C), indicating that Celastrol may affect the
structural integrity of tubulin heterodimer.
The biogenesis of tubulin heterodimer is tightly regulated, and
the damaged tubulins are subjected to degradation or recycling
pathway that involves the tubulin-specific cofactors [32]. To test if
Celastrol affects the level of tubulin in vivo, we treated HEK293
cells with Celastrol for 1 hr, and the levels of tubulin along with
other cellular proteins were examined. Interestingly, the level of
both alpha- and beta-tubulin was significantly reduced, while that
of MT-associated motor protein components (Dynactin p150 and
dynein IC) or other known targets of the proteasome and HSP90
pathway, such as IGF receptor, IRS-1, and Akt was not changed
(Figure 4D). The level of gamma-tubulin was slightly increased or
unaffected by Celatrol treatment (Figure 4D and Figure S4).
Perturbation of MT structures affects the activity of cyclin-
dependent kinases (CDKs) in vivo, leading to an enhanced
phosphorylation of target proteins [33,34]. The reduction of
tubulin level by Celastrol may lead to MT structural defects and
affect the phosphorylation status of CDKs target proteins.
Consistent with this prediction, the levels of phosphorylation of
lapse movie was taken in a drug-free medium. (D) Quantification of cell migration. The relative migration area over the control (DMSO-treated) was
presented. * indicates p,0.05 by student T-test.
doi:10.1371/journal.pone.0010318.g001
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PLoS ONE | www.plosone.org 5 April 2010 | Volume 5 | Issue 4 | e10318Figure 2. Celastrol inhibits mitotic progression and chromosome alignment. (A) HEK293 cells were treated with Celastrol (2 mM) for 1 hour before
fixation and staining with DAPI. The mitotic cells were counted and scored according to their chromosomal morphology. The proportion of each mitotic stage
over the total number of counted cells was presented. (B) HeLa cells were treated with Nocodazole (100 nM) for 6 hours. The arrested cells were collected by
tapping the plate, washed in PBS, and replated in a serum free medium. After 15 minutes of attachment (time 0), each drug was added and incubated for 30
minutes before fixation and staining with DAPI. The average number of cells in each stage from the quadruplicates was shown. ‘ND’ indicates the non-mitotic
or dead cells. (C) Hela cells over-expressing EGFP-H2B protein were treated with indicated drugs. Immediately following drug addition, the prophase cells were
identified and the time-lapse images were taken every 5 minutes for 90 minutes. The magnified still images from the representative movies were shown. (D)
The summary of time-lapse movies for mitotic chromosome alignment in C). The degree of mitotic progression of prophase cells in 60 minutes in the presence
of each chemical was determined based on chromosomal shape, and was indicated by horizontal bar. Numbers indicate number of cells examined. The
representative chromosomal shapes of control cells at different mitotic stages were shown in lower panel as a reference.
doi:10.1371/journal.pone.0010318.g002
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Celastrol (Figure 4D). Collectively, these results suggest that
Celastrol alters MT functions by directly targeting tubulin
heterodimer.
Taxol-resistant cancer cells remain sensitive to Celastrol-
induced apoptosis
The MT stabilizer Taxol is one of the most widely used anti-
cancer agents. However, some cancer cells develop a resistance,
and such resistant cancer cells may further accumulate the
genomic instability, contributing to more malignant transforma-
tion. Celastrol has been shown to have anti-cancer properties
[19,20,21,35]. We demonstrated that it regulates MT function via
a different mechanism. Thus we next explored if Celastrol could
be still effective to Taxol-resistant cancer cells. For this purpose,
we generated a Taxol-resistant HeLa cell line, which constitutively
express EGFP-H2B proteins, allowing us to identify cells at each
cell-cycle stage. In any given time, approximately 50% of Taxol-
resistant cells displayed the multiple nuclei phenotype, indicating
the uncoupling of chromosome segregation with cytokinesis
(Figure 5A). Compared with the parental cells, Taxol-resistant
cells showed a significant resistance toward Taxol-induced cell
death (Figure 5B). However, upon Celastrol treatment, these cells
still manifested a similar dose-dependent reduction of cell viability
Figure 3. Celastrol disorganizes mitotic spindles. The representative immunostaining of microtubule (alpha- tubulin) and centrosome
(gamma-tubulin) of the interphase and spindle morphology of mitotic HeLa cells treated for 1 hour with the indicated drugs; Celastrol (4 mM),
Vinblastine (10 nM), and Taxol (10 nM).
doi:10.1371/journal.pone.0010318.g003
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confirmed by a similar dose-dependent sensitivity and apoptotic
capacity of Taxol-resistant cells when treated with Celastrol,
compared to normal Hela cells (Figure 5D).
Celastrol selectively kills mitotic arrested cells
Regardless of differences in the mode of action, the utility of
MT drugs as anti-cancer agents is primarily due to their ability to
cause mitotic cell death. However, inhibition of MT functions can
also lead to perturbation of normal cellular functions. Therefore,
chemicals that facilitate mitotic death (i.e. proliferating cancer
cells) present a great potential to enhance the efficacy of MT
drugs. We found that Celastrol showed a synergistic apoptotic
activity when sequentially treated with various conventional MT
drugs (Figure S5). However, it is not known if Celastrol
preferentially affect the mitotic-arrested cells or drug-exposed
interphase cells. To specifically address this issue, we employed a
time-lapse live cell imaging and tracking assay using Hela cells
expressing EGFP-H2B protein. The drug-arrested mitotic cells are
easily distinguishable from the drug-exposed interphase cells,
based on the GFP-positive chromosome structure and their round
shape morphology (Figure S6A). Also, the apoptotic cells can be
identified when the plasma membrane collapses (or ‘membrane
blebbing’) as they die (Figure S6B and C).
Cells were pre-treated with Vinblastine (10 nM) for 4 hours to
induce mitotic arrest. Then, various pharmacological agents were
subsequently added and the time-lapse images were taken for
4 hours. The apoptotic death of pre-arrested mitotic cells and non-
mitotic cells were assessed (Figure 6A and B). Within this
experimental time period, Vinblastine alone failed to induce cell
death, although it induced mitotic arrest. This was also the case
even in the presence of a higher concentration (100 nM) of
Vinblastine for up to 12 hours (data not shown).
Intriguingly, when subsequently treated with Celastrol, the pre-
arrested mitotic cells preferentially underwent apoptosis (Table 1,
Figure 6A and B). Cell death was reversed by co-treatment of a
caspase inhibitor zVAD, suggesting caspase-mediated apoptotic
pathway is involved in this process (Table 1, Figure 6A and B).
The inhibitors of other cellular pathways, such as HSP90 and NF-
kB, known to be affected by Celastrol, had no such effect.
Inhibition of PI3K-Akt pathway, a well-known cell survival signal,
failed to show any noticeable selective effects. In contrast, Akt
inhibitor and LY294002 (a PI3K inhibitor) appeared to enhance
apoptosis of both mitotic and non-mitotic cells (Figure 6A and
B). To determine the effects of Celastrol alone in control mitotic
cells, we first synchronized cells at G1/S phase by double-
thymidine block method [17] and the fate of cells entering mitosis
was examined (see Materials and Methods). Although the
efficiency was much reduced, compared with the ‘Vinblastine-
arrest’ mitotic cells, a significant fraction of normal mitotic cell also
underwent apoptosis (Table 1), suggesting that mitotic cells are
intrinsically sensitive to Celastrol-induced cell death. This finding
may explain the synergistic apoptotic activity of Celastrol in
combination with various microtubule drugs, including Taxol,
Figure 4. Celastrol causes structural defects of tubulin in vitro and reduces its level in vivo. (A) HEK293 cell lysates were incubated in the
presence of the indicated amount of Celastrol or 18-beta GCA for 15 minutes prior to SDS-PAGE in non-reducing condition. The membrane was
blotted with the alpha-tubulin (top) or beta-tubulin antibody (bottom). (B) The cell lysates from control HEK293 cells were prepared and equally
divided into four different tubes, and immunoprecipitation was carried out with a polyclonal alpha-tubulin antibody in the presence of DMSO or
indicated amounts of Celastrol. After SDS-PAGE, the immune complex was blotted with the mouse monoclonal antibody against the alpha-, beta-, or
gamma-tubuln. The amount of alpha-tubulin (top panel) serves as a loading control. (C) The immunoprecipitation and Western blot was carried out
as in B) in the presence of different chemicals. (D) HEK293 cells were treated with indicated amounts of Celastrol for 1 hour, and the whole cell lysates
were analyzed for the indicated cellular proteins. The same lysates were blotted with the phospho-CDK substrate antibody (right panel).
doi:10.1371/journal.pone.0010318.g004
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S5). Previously, it has been shown that genetic or pharmacological
inhibition of CDKs led to a massive cell death in Taxol-arrested
cancer cells [33]. Consistent with this finding, we also observed an
increased apoptosis in the presence of CDK inhibitors (Table 1
and Figure S7). However, unlike the inhibitors of CDKs,
Celastrol did not inhibit either the basal or Vinblastine-induced
phosphorylation of CDK target proteins (Figure 6C). In addition,
in contrast to Celastrol, we found no obvious MT defects in both
interphase and mitotic cells treated with CDK inhibitors (Figure
S8). These findings indicate that the molecular mechanisms by
which Celastrol enhances the mitotic death are different or, at
least, not through direct inhibition of CDK activity.
Discussion
Chemical compounds from natural sources continue to serve as
important pharmacological tools for the understanding of
biological pathways and provide critical chemical platforms for
new drug discovery. The utility of various anti-microtubule agents
from natural origins is the best example that continuously serves
these two purposes. In this study, we identified a novel tubulin-
targeting activity of a natural product Celastrol, and demonstrated
that this unique activity, in combination with conventional
microtubule-targeting anti-cancer drugs, could be exploited to
selectively induce apoptotic cell death of mitotic cells.
Identification of tubulin as a primary target of Celastrol explains
many of its cellular and biological effects. For instance, Celastrol
was derived from the plant extracts used for the treatment of
inflammatory symptoms in traditional medicine [18]. This anti-
inflammatory effect can be directly attributed to inhibition of MT-
mediated cellular processes, such as migration of immune cells and
secretion of inflammatory cytokines. This view is consistent with
the fact that Colchicine, an MT destabilizer, is one of the earliest
medicines used for the treatment of inflammatory gout disease.
This initial effect could be accompanied by the subsequent
transcriptional repression of pro-inflammatory genes through
inhibition of NF-kB activation by Celastrol [22,36].
Some of the anticancer activity of Celastrol may come from
inhibition of proteasome, HSP90, or NF-kB pathway as previously
reported [19,20,21,22,36]. However, the known inhibitors of these
pathways had little effect on apoptosis of MT drug-arrested mitotic
cells. Therefore, under this experimental condition, inhibition of
these pathways does not appear to be the main cause of Celastrol-
induced mitotic cell death. Intriguingly, in a gene expression-based
in silico screen, Celastrol was identified as a compound with the
‘parthenolide (PTL)-like’ gene expression signature. It was shown
that, like PTL, Celastrol selectively eradicated leukemic stem cells
through inhibition of NF-kB survival pathway [35]. However, of
note is the report that PTL inhibited the antigen-induced
microtubule formation and degranulation of master cells indepen-
dent of NF-kB inhibition [37]. This finding is further supported by
a recent discovery of PTL as a chemical inhibitor of tubulin
carboxypeptidase, which involves in the regulation of alpha
tubulin tyrosination [38]. Thus, it appears that, like Celastrol,
the microtubule-inferring activity of PTL can also contribute to its
anti-cancer properties.
The molecular mechanisms underlying the enhanced killing of
MT drug-arrested mitotic cells by Celastrol are the subject of
future investigations. However, we ruled out the possibility that
Celastrol simply inhibited the cell survival pathway(s). For
example, it may be speculated that, due to a loss or reduction of
the contact with the substratum, the MT drug-arrested mitotic
cells are intrinsically more susceptible to apoptotic stimuli. If this is
the case, inhibition of general cell survival pathways, such as
PI3K-Akt and NF-kB, may result in a similar selective killing
effect. However, our data did not support this prediction. Other
Figure 5. Taxol-resistant cancer cells remain sensitive to Celastrol-induced apoptosis. (A) The multinuclei phenotype of Taxol-resistant
HeLa cells expressing Histone H2B-EGFP. Arrows indicate the cells with the multiple nuclei, and approximately 50% of cells displayed this phenotype.
(B) The bright field images of parental and Taxol-resistant cells treated with Taxol (20 nM) for 36 hour or Celastrol (4 mM) for 24 hours. The
percentage of dead cells was quantified based on the nuclear morphology as determined by Histone H2B-EGFP, and cells with the fragmented nuclei
were counted as dead cells (right panel). (C) The sensitivity of parental and Taxol-resistant cells toward Taxol or Celastrol. Each cell line was treated
with the indicated amounts of Taxol for 36 hours or Celastrol for 24 hours, and the cell viability was determined by MTT assay. The relative activity
with respect to vehicle alone (DMSO) was presented. (D) The parental and Taxol-resistant cells were treated with DMSO or Celastrol (4 mM) for
6 hours, and the cytosolic cell lysates were subjected to caspase activity assay. The relative caspase activity over DMSO treatment was presented.
doi:10.1371/journal.pone.0010318.g005
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reported to interfere, also failed to exert a similar effect. Another
possibility might be that Celastrol inhibits the activity of CDKs,
which have been shown to result in a massive cell death in Taxol-
arrested cancer cells [33]. Consistent with this finding, the
chemical inhibitors of CDKs led to apoptosis in a manner
correlated with their activity to inhibit the phosphorylation of
target proteins. However, Celastrol did not affect the phosphor-
ylation status of CDKs target proteins, making this possibility also
very unlikely.
What could be responsible for this selective killing effect? We
showed that Vinblastine alone was not sufficient to induce mitotic
cell death within our experimental time period, whereas Celastrol
alone caused some degree of apoptosis, indicating that mitotic cells
are intrinsically sensitive to Celastrol. This observation is
consistent with the synergistic apoptotic effect of Celastrol with
various MT drugs that induce mitotic arrest in different
mechanisms. We showed that, unlike other MT drugs, Celastrol
disrupted tubulin heterodimer in vitro. Can disrupting tubulin
heterodimer be a contributing factor for cell death? This possibility
assumes that the structural defects or modifications of tubulin
perturb the additional cellular pathways that contribute to cell
death. This view is consistent with the studies showing that the
cytotoxic effects of natural and synthetic chemicals are closely
associated with their activity to target tubulins [39,40,41,42,43].
Celastrol may also cause an enhanced turnover of tubulin
heterodimer through the structural defects. We showed that
Celastrol directly affected the structural integrity of tubulin in vitro.
It could be possible that such binding may influence the in vivo
modifications of tubulin, such as tyrosination. In this respect, it is
Figure 6. Celastrol selectively kills mitotic arrested cells. (A) The time-lapse images of Vinblastine-arrested cells treated with different
chemicals. The magnified still images were shown for the clarity. The pre-arrested mitotic or interphase cells to die within 150 minutes were indicated
by red and blue arrows, respectively. (B) Quantification of mitotic or non-mitotic cell death. The percentage of dying cells over total number of cells in
mitotic or interphase state at time 0 was presented. (C) Celastrol did not inhibit Vinblastine-induced phosphorylation of CDK target proteins. Cells
were treated with each drug for 1 hour or pre-treated with Vinblastine (100 nM) for 30 minutes followed by subsequent drug treatment for 1 hour.
The whole cell lysate was analyzed with the phospho-CDKs substrate antibody, and the same blot was probed with the actin antibody for loading
control.
doi:10.1371/journal.pone.0010318.g006
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with the ‘PTL-like’ functional property [35]. PTL has anti-cancer
activities, and was shown to inhibit tubulin tyrosination [44],
which is required for the recruitment of the CAP-Gly (cytoskel-
eton-associated protein-glycine-rich) domain-containing proteins
to MTs. Defects in tubulin tyrosination led to mislocalization of
these proteins, resulting in spindle defects during mitosis [6,44].
The mitotic spindle defects caused by Celastrol could be
attributable to such changes.
In summary, we identified a novel tubulin-targeting activity of
Celastrol and demonstrated its utility as an enhancer of mitotic cell
death. Therefore, we provide a molecular explanation for its anti-
inflammatory and anti-cancer activity, and present a chemical tool
to elucidate the molecular mechanisms underlying the mitotic cell
death and to enhance the efficacy of MT drugs.
Supporting Information
Figure S1 Celastrol causes defects in centrosomal positioning in
mitotic cells. The representative staining of gamma- and alpha-
tubulin in mitotic cells treated with DMSO (A) or Celastrol (4 uM)
for 1 hour (B). The prometaphase or metaphase of control mitotic
cells was identified based on chromosomal morphology as
visualized by DAPI staining. The images of Celastrol-treated
mitotic cells were taken at two different focal planes, focusing on
each gamma-tubulin, and the corresponding alpha-tubulin
staining was shown to reveal the degree of spindle disorganization.
Found at: doi:10.1371/journal.pone.0010318.s001 (0.69 MB TIF)
Figure S2 Oigomerization of purified tubulin. A) The purified
tubulin was incubated for the indicated time and run on SDS-
PAGE in non-reducing or reducing condition, and blotted with
the alpha-tubulin antibody. B) HEK293 cell lysates or purified
tubulin was incubated in the presence or absence of ATP or GTP
for 15 minutes, and analyzed for the oligomer formation in non-
reducing condition.
Found at: doi:10.1371/journal.pone.0010318.s002 (0.14 MB TIF)
Figure S3 Celastrol inhibits oligomerization of purified tubulin.
The purified tubulin was incubated in the presence of increasing
amount of Celastrol or 18-beta GCA for 60 minutes, and analyzed
with the mouse monoclonal alpha-tubulin antibody.
Found at: doi:10.1371/journal.pone.0010318.s003 (0.11 MB TIF)
Figure S4 The level of gamma-tubulin was unaffected by
Celatrol treatment. HEK293 cells were treated with the different
amounts of Celastrol for 1 hour and the whole cell lysates were
analyzed for the level of beta-tubulin, gamma- tubulin, or Akt.
Found at: doi:10.1371/journal.pone.0010318.s004 (0.08 MB TIF)
Figure S5 The synergistic apoptotic effects of Celastrol with
conventional microtubule drugs. Cells were pre-treated with each
microtubule drug (10 nM) for 4 hour and then treated with
Celastrol (4 uM) for additional 4 hour prior to the caspase activity
assay. The relative activity was normalized against Celastrol
treatment (4 hr) only.
Found at: doi:10.1371/journal.pone.0010318.s005 (0.06 MB TIF)
Figure S6 Identification of mitotic cells and apoptotic cells. A)
The cell shape and chromosomal morphology of the interphase or
mitotic-arrested cells. B) Apoptotic death of mitotic cells. Numbers
indicate time after Vinblastine (100 nM) treatment. C) Apoptotic
death of non-mitotic cells pre-treated with Vinblastine (10 nM for
4 hours) followed by LY294002 treatment (20 uM). Numbers
indicate time after LY294002 (see Figure 6 for details).
Found at: doi:10.1371/journal.pone.0010318.s006 (0.32 MB TIF)
Figure S7 Effects of chemical inhibitors of CDKs on mitotic cell
death. Cells were pre-treated with Vinblastine (10 nM) for 4 hours
and subsequently treated with each chemical (10 uM) for
additional 4 hours.
Found at: doi:10.1371/journal.pone.0010318.s007 (0.26 MB TIF)
Figure S8 CDK inhibitor does not cause microtubule defects.
Representative immunostaining of interphase microtubules and
mitotic spindles of HeLa cells treated with Purvalanol A (10 uM)
for 1 hour.
Found at: doi:10.1371/journal.pone.0010318.s008 (0.39 MB TIF)
Movie S1 fMLP-induced neutrophil chemotaxis
Found at: doi:10.1371/journal.pone.0010318.s009 (0.72 MB
WMV)
Table 1. Effect of pharmacological agents on mitotic cell death.
Tested chemicals Targets # cells examined # cells dead % cell death
Vinblastine Only MT destablizer 98 11 11.2
Celastrol only (4 mM) Tubulin binding 72 25 34.7
Celastrol (2 mM) 69 27 39.1
Celastrol (4 mM) 61 43 70.5
18-bGCA (20 mM) Structurally analogous 22 4 18.2
to Celastrol
17AAG (8 mM) HSP90 16 2 12.5
MG132 (5 mM) Proteasome 30 0 0
Etoposide (10 mM) Topoisomerase 30 6 20
Bay 11-7085 (20 mM) NF-kappa B 27 1 3.7
Resveratrol (20 mM) Antioxidant 22 1 4.5
Akt-i VIII (7.6 mM) Akt 28 5 17.9
LY294002 (20 mM) PI3K 36 10 27.8
HeLa cells expressing EGFP-Histone H2B (HeLa-H2B) were arrested at mitotic phase by Vinblastine treatment, and the indicated amounts of each drug was added. The
apoptotic death of only the ‘pre-arrested’ mitotic cells in 4 hours as identified by time-lapse movie was scored. ‘Vinblastine only’ indicates without addition of other
drugs and ‘Celastrol only’ indicates its effect on normal mitotic cells (see Materials and Methods).
doi:10.1371/journal.pone.0010318.t001
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Found at: doi:10.1371/journal.pone.0010318.s010 (0.73 MB
WMV)
Movie S3 Migration of Hela cells toward wounded area.
Found at: doi:10.1371/journal.pone.0010318.s011 (0.64 MB AVI)
Movie S4 Effect of Celastrol on migration of Hela cells.
Found at: doi:10.1371/journal.pone.0010318.s012 (0.64 MB AVI)
Movie S5 Chromosomal behavior of mitotic cells.
Found at: doi:10.1371/journal.pone.0010318.s013 (1.15 MB AVI)
Movie S6 Effect of Celastrol on behavior of mitotic chromo-
somes.
Found at: doi:10.1371/journal.pone.0010318.s014 (1.15 MB AVI)
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